Jul 30, 2025
Veloxis Pharmaceuticals to Present at 2025 World Transplant Congress
Feb 25, 2025
Veloxis Pharmaceuticals Receives Approval from USAN for "Pegrizeprument" as Nonproprietary Name for VEL-101
May 30, 2024
Veloxis Pharmaceuticals Selected to Present at the 2024 American Transplant Congress in Philadelphia
Jun 22, 2020
Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program
Dec 17, 2019
Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair
Nov 12, 2019
Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2019
Oct 30, 2019
Veloxis Increases Outlook for 2019 Based on Continued Strong Performance
Jul 22, 2019
Veloxis Revises Outlook for 2019 Based on Strong Performance
May 31, 2019
Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress
May 06, 2019
Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2019
Jan 02, 2019
Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals
Nov 14, 2018
Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights
Oct 31, 2018
Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S
Oct 10, 2018
Veloxis to Present at the Jefferies 2018 London Healthcare Conference
Aug 13, 2018
Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2018
May 15, 2018
Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
Apr 20, 2018
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
Apr 03, 2018
Veloxis Appoints Morten Marott as Chief Financial Officer
Mar 28, 2018
Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®
Mar 22, 2018
Notice to Convene Annual General Meeting 2018